Patents Assigned to Japanese Foundation for Cancer Research
  • Patent number: 11419871
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: August 23, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • Patent number: 11415584
    Abstract: The therapeutic effect of and/or prognosis after administration of an anti-VEGFR-2 antibody drug, in particular, ramucirumab can be predicted by measuring VEGF-A, VEGF-D, sVEGFR-2, SDF-1?, and/or cNRP1. Provided is a biomarker for predicting the effect of administration of the anti-VEGFR-2 antibody drug, in particular, ramucirumab, and a test method and a test kit using the marker.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: August 16, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Tetsuo Mashima, Takeru Wakatsuki, Hiroyuki Seimiya, Kensei Yamaguchi
  • Patent number: 11414429
    Abstract: Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 16, 2022
    Assignees: RIKEN, JAPANESE FOUNDATION FOR CANCER RESEARCH, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Minoru Yoshida, Hiroyuki Seimiya, Masayuki Okue, Yoko Yashiroda, Fumiyuki Shirai, Takeshi Tsumura, Yuko Kano, Kenichi Washizuka, Nobuko Yoshimoto, Yasuko Kouda, Takehiro Fukami, Tsubasa Chikada, Takashi Watanabe
  • Publication number: 20220178932
    Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).
    Type: Application
    Filed: April 15, 2020
    Publication date: June 9, 2022
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY, TOSOH CORPORATION
    Inventors: Koji UEDA, Naomi OHNISHI, Kazutake TSUJIKAWA, Norio NONOMURA, Motohide UEMURA, Kentaro JINGUSHI, Norihisa OHTAKE, Yasutoshi KAWAI
  • Patent number: 11340215
    Abstract: The inventors have found that the interaction between HP1 and INCENP can serve as an indicator for chromosome instability and established a method for evaluating chromosome instability of cancer cells. The evaluation system can be used for screening of anticancer agent with a new-concept of targeting chromosome instability of cancer cells. The inventors further prepared an antibody for specifically recognizing phosphorylation of serine at position 92 of HP1?, by which the action of Aurora B can be evaluated. The interaction between HP1 and INCENP can be readily evaluated by the antibody.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 24, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Toru Hirota, Yusuke Abe
  • Patent number: 11286261
    Abstract: Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the like, and the like.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 29, 2022
    Assignees: NAGASAKI UNIVERSITY, IWATE MEDICAL UNIVERSITY, JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Masatomo Iwao, Tsutomu Fukuda, Fumito Ishibashi, Yoshimasa Uehara, Naoyuki Nishiya, Yusuke Oku, Shingo Dan, Takao Yamori
  • Publication number: 20210403555
    Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 30, 2021
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, API CO., LTD.
    Inventors: Nobuhiko GYOBU, Naoya FUJITA, Mamoru KAKINO, Ai KAWASHIMA, Shinya FUJIHARA, Naoki GODA
  • Publication number: 20210407654
    Abstract: Provided is an information processing apparatus including an image supply unit that supplies a plurality of input images showing corresponding objects to an image processing unit and obtains a plurality of object images as an image processed result from the image processing unit, and a display control unit that synchronously displays the plurality of object images that have been obtained. The object images are regions including the corresponding objects extracted from the plurality of input images, and orientations, positions, and sizes of the corresponding objects of the plurality of object images are unified.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Applicants: Sony Group Corporation, Japanese Foundation For Cancer Research
    Inventor: Takeshi Ohashi
  • Patent number: 11142801
    Abstract: It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 12, 2021
    Assignees: JAPANESE FOUNDATION FOR CANCER RESEARCH, SEKISUI MEDICAL CO., LTD.
    Inventors: Masami Arai, Sachio Nomura, Yuriko Nemoto, Takuya Yotani
  • Publication number: 20210100885
    Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 8, 2021
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, THE JIKEI UNIVERSITY
    Inventors: Masaki ITO, Kiyotaka SHIBA
  • Publication number: 20210100884
    Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 8, 2021
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, THE JIKEI UNIVERSITY
    Inventors: Masaki ITO, Kiyotaka SHIBA
  • Patent number: 10955410
    Abstract: A coating agent for preventing the adsorption of extracellular vesicles represented by exosomes to a tool has been developed. Adsorption of extracellular vesicles to a tool can be prevented by using a coating agent which contains a hydrophilic polymer having a weight average molecular weight of 10,000 or more and 1,000,000 or less, wherein a coated layer formed by the coating agent has a contact angle of 0 degree or more and 30 degrees or less.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: March 23, 2021
    Assignees: JAPANESE FOUNDATION FOR CANCER RESEARCH, NOF CORPORATION
    Inventors: Kiyotaka Shiba, Nobuyuki Sakamoto, Tomozumi Noda, Satoshi Yamada
  • Publication number: 20210060016
    Abstract: To provide an anticancer agent for preventing and/or treating cancer, comprising a tankyrase inhibitor containing a tankyrase inhibitory compound and a microtubule inhibitor containing a microtubule inhibitory compound as active ingredients.
    Type: Application
    Filed: December 26, 2018
    Publication date: March 4, 2021
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, RIKEN, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Hiroyuki SEIMIYA, Minoru YOSHIDA, Yoko YASHIRODA, Yukiko MURAMATSU, Fumiyuki SHIRAI, Kenichi WASHIZUKA
  • Publication number: 20210061789
    Abstract: Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH; r represents 0 to 4; each R101 is the same or different when r is 2 or more, and R101 represents a C1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R102 is the same or different when s is 2 or more, and R102 represents a halogen atom or the like; R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position.
    Type: Application
    Filed: December 26, 2018
    Publication date: March 4, 2021
    Applicants: RIKEN, JAPANESE FOUNDATION FOR CANCER RESEARCH, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Minoru YOSHIDA, Hiroyuki SEIMIYA, Yoko YASHIRODA, Kenichi WASHIZUKA, Fumiyuki SHIRAI, Nobuko YOSHIMOTO, Junichi KAZAMI
  • Patent number: 10921311
    Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 16, 2021
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Kengo Takeuchi, Seiji Sakata, Yuki Togashi, Naoya Fujita, Ryohei Katayama
  • Patent number: 10898555
    Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: January 26, 2021
    Assignees: JAPANESE FOUNDATION FOR CANCER RESEARCH, THE JIKEI UNIVERSITY
    Inventors: Masaki Ito, Kiyotaka Shiba
  • Patent number: 10813933
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 27, 2020
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • Patent number: 10730939
    Abstract: A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 4, 2020
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Naoya Fujita, Takaya Sekiguchi, Satoshi Takagi
  • Patent number: 10705087
    Abstract: A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an NTRK3 fusion protein, or a fusion gene encoding the fusion protein, or an ETV6 fusion protein, or a fusion gene encoding the fusion protein, in a sample derived from the digestive system obtained from a subject, is detected.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: July 7, 2020
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Kengo Takeuchi, Yuki Togashi, Seiji Sakata, Satoko Baba
  • Publication number: 20200172874
    Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicants: TOPPAN PRINTING CO., LTD., Japanese Foundation For Cancer Research
    Inventors: Yuki TAKAHASHI, Shiro KITANO, Ryohei KATAYAMA, Satoshi NAGAYAMA